6 recruiting, 4 completed, 3 active not recruiting, 1 not yet recruiting. 11 Phase 2, 6 Phase 1, 1 Phase 3.
Follow YESCARTA: new trials by email Literature Review of YESCARTA trials Research Report on YESCARTA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-11-01 | 2026-11-12 |
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-11-04 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-05-19 | 2026-09-16 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-11-04 |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) KYMRIAH, YESCARTA - Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL) | Completed | Novartis Pharmaceuticals | 273 | 2020-12-09 | 2022-07-01 | |
| Axi-cel in CNS Lymphoma Fludarabine, Cyclophosphamide, Axicabtagene Ciloleucel - Lymphoma, Lymphoma Cns | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 18 | 2020-12-04 | 2026-08-12 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2020-07-27 | 2025-01-28 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Itacitinib, Immune effector cell therapy, Placebo - Cytokine Release Syndrome | Phase 2 | Completed | Incyte Corporation | 112 | 2020-02-07 | 2024-03-26 |
| MT2017-45: CAR-T Cell Therapy for Heme Malignancies KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses - Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 150 | 2018-12-18 | 2026-01-23 |
Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Non-Hodgkin (3) · Lymphoma (2) · Lymphoma, B-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Cytokine Release Syndrome (1) · Disease Progression (1) · HIV Infections (1) · Hematologic Neoplasms (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1)
Masonic Cancer Center, University of Minnesota (2) · University of Michigan Rogel Cancer Center (2) · AIDS Malignancy Consortium (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Incyte Corporation (1) · Jonsson Comprehensive Cancer Center (1) · Lyell Immunopharma, Inc. (1) · M.D. Anderson Cancer Center (1) · NeoImmuneTech (1) · Novartis Pharmaceuticals (1) · SWOG Cancer Research Network (1) · University of Washington (1)
United States (16) · Australia (1) · Canada (1)
Ajay Gopal (1) · Ariela Noy (1) · Brian T Hess (1) · Caron Jacobson, MD (1) · John DiPersio, M.D. (1) · John M Timmerman, MD (1) · Karamjeet S Sandhu (1) · Marcus Geer (1) · Michael Jain, MD, PhD (1) · Monalisa Ghosh (1) · Paolo Strati (1) · Peter Langmuir, MD (1) · Veronika Bachanova, MD (1) · Veronika Bachanova, MD, PhD (1)
PMID 32998963, PMID 38022532, PMID 40090005
P30CA033572 (1), U10CA180888 (1), UM1CA121947 (1)